NF-κB

nwamba # Aha ngwaahịa Nkọwa
CPD3237 CDDU-M
CPD3619 CPD3619
CPD3236 CPD3236
CPD3235 CPD3235
CPDD0995 Bardoxolone methyl Oleanane triterpenoid CDDO synthetic (Ngwa nke No. 81035) bụ Nrf2 activator nke na-egbochi mgbasawanye ma na-ebute ọdịiche na apoptosis na mkpụrụ ndụ cancer dị iche iche.
CPD1017 Bardoxolone Bardoxolone bụ ihe na-ahụ maka nchịkwa nuklia ọhụrụ (Nrf-2) activator.
CPDB1661 IT-901 IT-901 bụ c-Rel Inhibitor nke na-emezi Njirimara Anticancer na Hematologic Malignancies site na igbochi NF-κB-Controlled Oxidative Stress Responses.
nke

Kpọtụrụ anyị

Ajuju

Akụkọ kacha ọhụrụ

  • Usoro 7 kachasị na nyocha ọgwụ na 2018

    Usoro 7 kacha elu na nyocha ọgwụ m...

    N'ịbụ ndị nọ n'okpuru nrụgide na-arịwanye elu mgbe niile ịsọ mpi na gburugburu ebe obibi akụ na ụba na nkà na ụzụ siri ike, ụlọ ọrụ ọgwụ na biotech ga-anọgide na-emepe emepe na mmemme R&D ha iji nọgide na-aga n'ihu ...

  • ARS-1620: Onye mmechi ọhụrụ na-ekwe nkwa maka ọrịa cancer KRAS-mutant

    ARS-1620: ihe mgbochi ọhụrụ na-ekwe nkwa maka K…

    Dị ka otu nnyocha e bipụtara na Cell si kwuo, ndị nchọpụta ewepụtala ihe mgbochi kpọmkwem maka KRASG12C nke a na-akpọ ARS-1602 nke na-eme ka ụbụrụ tumor regression na ụmụ oke. "Ọmụmụ ihe a na-enye na vivo ihe akaebe na mutant KRAS nwere ike ịbụ ...

  • AstraZeneca na-enweta nkwalite nchịkwa maka ọgwụ oncology

    AstraZeneca na-enweta nkwalite nchịkwa maka ...

    AstraZeneca nwetara nkwalite okpukpu abụọ maka pọtụfoliyo oncology ya na Tuesday, mgbe ndị na-ahụ maka US na European nabatara ntinye iwu maka ọgwụ ya, nzọụkwụ mbụ iji nweta nkwado maka ọgwụ ndị a. ...

Mkparịta ụka WhatsApp n'ịntanetị!